---
title: "Guggenheim Remains a Hold on Exelixis (EXEL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285502987.md"
description: "Guggenheim has maintained a Hold rating on Exelixis (EXEL), with shares closing at $48.70. The analyst consensus suggests a Moderate Buy rating with an average price target of $48.00, indicating a potential downside of 1.44%. Barclays also holds a Hold rating with a price target of $45.00."
datetime: "2026-05-07T07:25:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285502987.md)
  - [en](https://longbridge.com/en/news/285502987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285502987.md)
---

# Guggenheim Remains a Hold on Exelixis (EXEL)

In a report released yesterday, from Guggenheim maintained a Hold rating on Exelixis. The company’s shares closed yesterday at $48.70.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $48.00 average price target, which is a -1.44% downside from current levels. In a report released yesterday, Barclays also maintained a Hold rating on the stock with a $45.00 price target.

### Related Stocks

- [EXEL.US](https://longbridge.com/en/quote/EXEL.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL](https://longbridge.com/en/news/286523415.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)